Description
Vaccine inequality & low public acceptance inhibit vaccine uptake and limit coverage. Approximately 25m children under 1 year of age did not receive basic vaccines (highest since 2009). Global vaccine coverage dropped during COVID pandemic to 81%, and only 29% of the population in developing countries was vaccinated against Covid. Our HIP-Vax platform can help solve these issues by shortening the time to the clinic and greatly reducing vaccine manufacturing costs. Our HIP-Vax platform helps make vaccines more affordable and allows for more equitable access.
Rapid esponse, low-cost manufacturing of viral vaccines against emerging infectious disease threats
June 29, 2023
11:00 - 12:00 CET
Zoom
Organisation:
Batavia Biosciences
Alfred Luitjens
Global Technical Sales Director - Batavia Biosciences
Alfred Luitjens is Global Technical Sales Director at Batavia Biosciences. He has a profound background in the development and production of vaccines, with more than 30 years of experience. He worked for research & development at Solvay, DSM Biologics and Crucell. He had a management position at the Animal Science Group and was a Senior Manager of Process Architecture at GSK. At Batavia Biosciences, Alfred is responsible for writing all project proposals and key account management, advising organizations worldwide on vaccine development.
